XML 61 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation (Tables)
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Schedule of Stock Option Valuation Assumptions  
The fair value of stock option awards in 2020 and 2019 was determined on the grant date using the Black-Scholes valuation model based on the following assumptions:
20202019
Expected term (years) (1)
5.96 – 6.02
5.27 – 6.02
Current stock value
$1.67 – $5.64
$1.28 – $1.67
Expected volatility (2)
49.3% – 51.9%
44.6% – 49.3%
Risk-free interest rate (3)
0.4% – 1.8%
1.6% – 1.9%
Dividend yield (4)
0 %0 %
(1)The expected term is the length of time the grant is expected to be outstanding before it is exercised or terminated. This number is calculated as the midpoint between the vesting term and the original contractual term (contractual period to exercise). If the option contains graded vesting, then the vesting term would be based on the vesting pattern.
(2)Volatility, or the standard deviation of annualized returns, was calculated based on comparable companies’ reported volatilities.
(3)Risk free rate was obtained from US treasury notes for the expected terms noted as of the valuation date.
(4)The Company has assumed a dividend yield of zero as it has no plans to declare dividends in the foreseeable future.
Schedule of Stock Option Activity
A summary of the Company’s stock option activity for the three months ended March 31, 2021 was as follows:
Number of
Common
Stock Options		Weighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic Value
(In Thousands)
Outstanding as of December 31, 202016,188,071 $1.67 
Granted— — 
Exercised(183,918)1.71 
Forfeited(227,782)1.71 
Outstanding as of March 31, 202115,776,371 1.71 8.83$356,546 
A summary of the Company’s stock option activity for the years ended December 31, 2020 and 2019 was as follows:
Number of
Common
Stock 
Options		Weighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic Value
(In
Thousands)
Outstanding as of December 31, 2018— $— 
Granted5,002,390 1.67 
Forfeited(14,313)1.67 
Outstanding as of December 31, 20194,988,077 1.67 
Granted12,904,692 1.67 
Forfeited(1,704,698)1.67 
Outstanding as of December 31, 202016,188,071 $1.67 9.35$523,401 
Vested and exercisable as of December 31, 20202,524,151 $1.67 8.87$81,612 
Vested and expected to vest as of December 31, 202016,188,071 $1.67 9.35$523,401 
Schedule of Restricted Stock Activity
Restricted stock awards activity for the three months ended March 31, 2021 was as follows:
SharesWeighted Average
Grant Date Fair Value
per Share
Outstanding as of December 31, 20201,815,891 $1.15 
Granted— — 
Forfeited(47,444)1.10 
Vested(357,808)0.83 
Outstanding as of March 31, 20211,410,639 1.13 
Employee restricted stock activity for the years ended December 31, 2020 and 2019 was as follows:
SharesWeighted Average
Grant Date Fair Value
per Share
Outstanding as of December 31, 201822,849,169 $0.22 
Granted2,055,545 1.29 
Forfeited(1,324,245)0.53 
Vested(17,333,998)0.14 
Outstanding as of December 31, 20196,246,471 0.80 
Granted— — 
Forfeited(1,667,349)0.86 
Vested(2,770,458)0.74 
Outstanding as of December 31, 20201,808,664 1.15 
Non-employee restricted stock activity for the years ended December 31, 2020 and 2019 was as follows:
SharesWeighted Average
Grant Date Fair Value
per Share
Outstanding as of December 31, 2018234,697 $0.11 
Granted— — 
Forfeited— — 
Vested(207,449)1.29 
Outstanding as of December 31, 201927,248 1.29 
Granted— — 
Forfeited(3,123)— 
Vested(16,898)1.29 
Outstanding as of December 31, 20207,227 1.29 
Schedule of Restricted Stock Units Activity
A summary of the Company’s restricted stock units activity for the three months ended March 31, 2021 was as follows:
SharesWeighted Average
Grant Date Fair
Value per Share
Outstanding as of December 31, 2020— $— 
Granted798,203 28.18 
Forfeited— — 
Vested— — 
Outstanding as of March 31, 2021798,203 28.18 
  
Schedule of Stock-based Compensation Expense by Function
Stock-based compensation expense by function was as follows (in thousands):
Three Months Ended March 31,
20212020
Cost of sales$83 $72 
Research and development762 435 
Sales and marketing186 82 
General and administrative806 540 
Total$1,837 $1,129 
Stock-based compensation expense by function was as follows (in thousands):
Year Ended December 31,
20202019
Cost of sales$309 $92 
Research and development2,098 914 
Sales and marketing414 163 
General and administrative5,890 1,533 
Total$8,711 $2,702